Sources Sought Notice – Q– Lab Testing & Interpretation for Cancer, Coagulation and Specialized Disease
| Federal Information & News Dispatch, Inc. |
Notice Type: Sources Sought Notice
Posted Date:
Office Address:
Subject: Q-- Lab Testing & Interpretation for Cancer, Coagulation and Specialized Disease
Classification Code: Q - Medical services
Solicitation Number: VA26014I1013
Contact: Jeffrey Abel360-852-9864 Email: [email protected] mailto:[email protected]
Setaside: N/AN/A
Place of Performance (address):
Place of Performance (zipcode): 97239
Place of Performance Country:
Description:
VA Northwest Health Network
VA Northwest Health Network
LABORATORY TESTING & INTERPRETATION OF SPECIMENS FOR CANCER, COAGULATION AND SPECIALIZED DISEASEFor
3710 SW US VETERANS HOSPITAL RD
1.0 GENERAL:
1.1 Authority: This contract is entered into under the authority of Public Law 104-262 and 38 U.S.C.8153. The contractor agrees to provide Health Care services in accordance with the terms and conditions stated herein at the
1.2 Services Required:
1.3 Place of Performance: The contractor will perform testing and interpretation at the contractors site.
1.4 Period of Performance: This will be a base period plus four 1-year options that may be exercised by PVAMC. No services shall be performed by the contractor after the base period without written approval from the contracting officer.
1.5 Scope of Work:
a. This contract is only for PVAMC. It will be a fixed firm price with estimated quantities. The contractor will be paid on a monthly basis for each month's pathology aid services in arrears.
b. Services outside the scope of work: Services outside the scope of this contract shall not be performed unless and until specifically authorized by the contracting officer. Any services performed without this authorization, (whether written or verbal), will be at the expense of the contractor.
c. The contractor performs testing and interpretation of PVAMC specimens.
1.5.1. Contractor's Specific Requirements:
1. Work Hours: NA
2. Personnel Policy: NA
3. Record Keeping: NA
4. Contract Performance Monitoring: see 7.1 Oversight of Service/Performance Monitoring
5. Key Personnel and temporary emergency substitutions: NA
2.0 PERSONNEL: NA
2.1. Qualifications:
2.2 Technical Direction:
1. Invoices: Invoices shall be submitted monthly in arrears with the following information
a. Contract number and purchase order number.
b. Station ID (648)
c. Date and times of service
d. Invoices will be billed as individual line items as they are listed in the price schedule
2. Monthly invoice(s) will contain only those items numbers used for that month. Invoices not received in proper format will be returned.
3. Marketing: Contractor shall not advertise or use any marketing material, logos, trade names, service marks, or other material belonging to the VA without consent.
2.3 Non-Personal Services: NA
3.0 HOURS OF OPERATION: NA
4.0 CONTRACTOR RESPONSIBILITIES: The contractor shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, interpretation of patient specimen testing listed below. All requirements and provisions defined in the specification of this solicitation will apply to any laboratory, i.e. branch, division, sub-contractor, etc. performing reference testing on behalf of the
Task 1. Contractor is responsible for providing requisition forms, special instructions, and current list of tests with reference ranges, turn-around-times and specimen requirement.
Task 2. Contractor is responsible for providing a secure interconnection between PLMS and the reference lab. The connection will transmit data to a dedicated printer at PLMS. The contractor will provide the dedicated printer and perform any maintenance the printer requires. This interconnection shall be protected through the use of VA approved encryption algorithms and products as required. Connections at each end shall be located within a controlled access site. All access shall be controlled by authentication methods to validate approved users.
Task 3. Contractor agrees not to use or disclose Protected Health Information (PHI) other than as permitted or required by the agreement or as required by law.
Task 4. Contractor agrees to use appropriate safeguards to prevent use or disclosure of the PHI other than is provided for by this agreement.
Task 5. Contractor agrees to report immediately any breach of safeguards and to mitigate any harmful effect related to the use or disclosure of PHI by the
Task 6. Contractor agrees to provide services during and after working hours.
Task 7. If applicable, the contractor agrees to transport samples in such a manner as to insure the integrity of the specimen.
Task 8. The contractor will comply with reporting test results with the specified time frame in accordance with the nature of the testing, following all regulatory requirements for reporting of patient results. Test results shall be reported within the specified times established by the
Task 9. The contractor will consult with PLMS on test result by telephone as needed.
Task 10. The contractor will provide PLMS with means of communication to the contractor to permit immediate inquiry regarding the status of pending tests.
Task 11. The contractor will provide data on tests not performed due to issues such as sample type, quantity or stability.
Task 12. The contractor will have the ability to provide test related information that can be used to help select the proper test and interpret results readily available and easy to access.
Task 13. The contractor will pick-up all specimens, at no-charge to the government.
LAB TESTING
Description Est Qnty for 1 yr Est $/ea Base Period Program
Hormone Receptors, ER, PR, EA 230 Cancer
IMMUNOHISTOCHEMISTRY 230 Cancer
MSI MULTIPLEX PCR 230 Cancer
MSI MULTIPLEX PCR 1ST 2 230 Cancer
MYELOPEROXIDASE STAIN 208 Cancer
SPECIAL STAIN OTHER 100 Cancer
IN SITU HYBRIDIZATION 230 Cancer
interphase 100-300 cells 245 Cancer
METHOTREXATE 230 Cancer
RETICULATED PLATELETS 100 Cancer
T CELL QUANT (T,B AND NK) 100 Cancer
Addl Karyotype simple 230 Cancer
Bone Marrow Chromosome 250 Cancer
ABL SEQ MOLE SEP BY CAP ELE 230 Cancer
BCR lysis of cells 230 Cancer
BCR NUCLEIC ACID PROBE 230 Cancer
BCR REVERSE TRANSICPTION 230 Cancer
BCR SIGNAL AMPLIFICATION 230 Cancer
JAK2 extraction HP 230 Cancer
JAK2 PCR 230 Cancer
JAK2 separation 230 Cancer
molecular probe 230 Cancer
EOSINOPHILS Fish Probe 230 Cancer
DVV confirm ratio 230 Coagulation
DVVT 230 Coagulation
Butyrate Esterase Stain 230 Coagulation
CNT 15-20 cells 2 karyotype 230 Coagulation
DECALIFICATION 230 Coagulation
Hem onc bld chromo 230 Coagulation
ANTI-B2-GLYCOPROTIEN ICG 230 Coagulation
ANTICARDIOLIPIN IGG or IGM 230 Coagulation
ANTITHROMBIN ACTIVITY 230 Coagulation
APTT 1"1 MIX 0 MIN 230 Coagulation
APTT PLASMA 60 MIN 230 Coagulation
FACTOR II ACTIVITY 230 Coagulation
FACTOR IX ACTIVITY 230 Coagulation
Factor V Activity 230 Coagulation
Factor V inhibitor 230 Coagulation
Factor VII Activity 230 Coagulation
FACTOR VIII COAG ACTIVITY 230 Coagulation
FACTOR VIII VWF AG 230 Coagulation
FACTOR X CHROMOGENIC 230 Coagulation
FACTOR XI ACTIVITY 230 Coagulation
FACTOR XII ACTIVITY 230 Coagulation
FACTOR XIII QUAL 230 Coagulation
HEPARIN EITHER STD/LMW 230 Coagulation
HEXAGONAL PL APTT 230 Coagulation
PLATELET FACTOR 4 W/REFLEX TO HAL 100 Coagulation
Platelet Function Analysis 100 Coagulation
VONWILL/RAF 100 Coagulation
OSMOLALITY, PLASMA 100 Instrument Backup
OSMOLALITY, URINE 100 Instrument Backup
PREP SURG SPEC LEVEL IV 100 Specialized Pathology
ELECTRON MICROSCOPY 250 Specialized Pathology
G6PD QUANT 230 Specialized Pathology
HISTOCHEMICAL STAIN WITH FS 230 Specialized Pathology
IMMUNOFLUORESCENCE (EA) 230 Specialized Pathology
MONOSPOT 230 Specialized Pathology
INTERPRETATION
Description CPT Est Quantity Base Period
Molecular diagnosis: interpretation and report 83912 400
Blood Smear peripheral interpretation with report 85060 380
Bone marrow smear interpretation, with or without differential cell count 85097 380
Cytopathology, concentration technique, smears and interpretation 88108 380
flow cytometry, interpretation; 2-8 markers 88187 300
flow cytometry, interpretation; 9-15 markers 88188 300
flow cytometry, interpretation; 16 or more markers 88189 300
Cytogentics and molecular cytogenetics, interpretation and report 88291 300
Level IV surgical pathology, gross and microscopic examination 88305 300
Special Stains, group II 88313 300
Special Stains, histochemical staining with frozen sections 88314 300
Determinative histochemistry or cytochemistry to identify exzyme constituents 88319 300
Consultation and report on referred slides prepared elsewhere 88321 298
immunocytochemistry (including immunoperoxidase) each antibody 88342 350
Immunoflourescent study, each antibody, direct method 88346 365
Electron microscopy, diagnostic 88348 395
Morphometric analysis, in situ hybridization 88368 396
Macroscopic examination, dissection, and preparation of tissue for non-microscopic analytical studies (nucleic acid-based molecular studies) 88387 400
5.0. DIRECT PATIENT CARE: NA
6.0. ADMINISTRATIVE: NA
7.0 GOVERNMENT RESPONSIBILITIES:
7.1 Oversight of Service/Performance Monitoring:
1. Oversight and performance monitoring will be accomplished by following the attached QASP. Services rendered will be verified PLMS staff, which assures the VA pays for only those services actually requested.
2. The services specified in this contract may be changed by written modification to this contract. The modification will be prepared and approved by the VA contracting officer prior to becoming effective.
3. ORDER OF PRECEDENCE: The terms, conditions, and attachments referenced herein, including any formal written modifications thereto, constitute the complete agreement between the parties and take precedence over any other language, oral or written.
4. Contracting Officer: The Contracting Officer (CO) is responsible for the overall administration of this contract. Contractor is advised that only the Contracting Officer, acting within the scope of his/her duties and responsibilities, has the authority to make changes to the contract, which affect contract prices, terms and conditions of this contract:
5. Governing Law: This contract shall be governed, construed and enforced in accordance with Federal Law.
8.0 Performance Standards, Quality Assurance And Quality Improvement. The contractor shall:
" Address all patient safety events as defined in VHA Handbook 1050.1 which include: Adverse events, Sentinel Events, Close Calls and intentionally unsafe acts.
" Ensure that upon notification of an unconfirmed patient safety event, it is immediately reported to the Contracting Officers representative.
" Ensure that patient safety events are confirmed, investigated, and resolved.
" Ensure that the Contracting Officers representative is informed throughout all investigations and that all findings and conclusions are reported to the Contracting Officers representative.
8.1 Methods of Surveillance: In accordance with the QASP.
8.2 Performance Standards:
Contract personnel shall be subject to the following standards and acceptable quality levels.
8.2.1 Standard 1 - Provides required service as specified in the contract.
Standard 1 - AQL: 100%
8.2.2 Standard 2 - Complies with all contract security requirements.
Standard 2 - AQL %100
8.2.3 Standard 3 - Completes all testing in a timely fashion in accordance with the contractors published Test Menu..
Standard 3 - AQL 100%
7.0. Special Contract Requirements: NA
7.1. Contractor Security Requirements: NA
Link/URL: https://www.fbo.gov/notices/7e87cac70993e17f79fcb61243e84543
| Copyright: | (c) 2013 Federal Information & News Dispatch, Inc. |
| Wordcount: | 1912 |
Combine Solicitation – Q– Reference Lab (Pathology Consulting/Testing)
Combine Solicitation – Marine Mammal Veterinary Services
Advisor News
- Embracing a family-centric approach to financial planning
- Family communication: Financial planning’s growing blind spot
- Americans aren’t turning retirement plans into action, LIMRA finds
- Ashley Hinson ‘death tax’ story collides with truth
- How advisors can prepare clients for an uncertain retirement landscape
More Advisor NewsAnnuity News
- Investigation finds deceptive sales, churning of annuities targeting postal workers
- Corebridge annuity sales slip ahead of Equitable marriage
- California teachers settle class-action lawsuit over in-plan annuity fees
- Jackson Financial CEO caps 40-year career with blockbuster Q2
- Lumos Insurance introduces the Immediate Care Plan to help families fund long-term care
More Annuity NewsHealth/Employee Benefits News
- NJ DEPARTMENT OF BANKING AND INSURANCE TO MAINTAIN THREE-MONTH OPEN ENROLLMENT PERIOD FOR GET COVERED NEW JERSEY DESPITE FEDERAL EFFORTS TO NARROW SIGN UP WINDOW
- HEALTH CARE PROVIDER PUTS ZACH LAHN ON BLAST FOR PLEDGING TO CONTINUE REYNOLDS' MEDICAID MISMANAGEMENT
- Medicare Reset Series 2027, Part 2: Difference between Supplements and Advantage Plans explained.
- California sets aside $250 million for public hospitals. Bay Area officials say it falls far short
- Louisiana hospitals see sharp uptick in uninsured patients after Obamacare subsidies expired
More Health/Employee Benefits NewsLife Insurance News
- Built to Last: Winston-Salem—a quiet industrial powerhouse
- The silver economy ushers in a new era of life insurance growth
- Family communication: Financial planning’s growing blind spot
- Indiana eyes more oversight of insurance companies' exposure to private credit
- HEALEY-DRISCOLL ADMINISTRATION RETURNS $14.5 MILLION TO HEALTH AND DENTAL INSURANCE CONSUMERS AND BUSINESSES
More Life Insurance News